Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC)
Background: Evidence on SARS-CoV-2 mRNA vaccination under siponimod treatment is rare. Methods: AMA-VACC is a prospective, open-label clinical study on SARS-CoV-2 mRNA vaccination during ongoing siponimod treatment (cohort 1), during siponimod interruption (cohort 2), or during treatment with other...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/8/1374 |
| _version_ | 1827058901821947904 |
|---|---|
| author | Tjalf Ziemssen Marie Groth Veronika Eva Winkelmann Tobias Bopp |
| author_facet | Tjalf Ziemssen Marie Groth Veronika Eva Winkelmann Tobias Bopp |
| author_sort | Tjalf Ziemssen |
| collection | DOAJ |
| description | Background: Evidence on SARS-CoV-2 mRNA vaccination under siponimod treatment is rare. Methods: AMA-VACC is a prospective, open-label clinical study on SARS-CoV-2 mRNA vaccination during ongoing siponimod treatment (cohort 1), during siponimod interruption (cohort 2), or during treatment with other disease-modifying therapies or without therapy (cohort 3). SARS-CoV-2-specific antibodies and T-cell reactivity were measured six months after the initial vaccination and one month after the booster. Results: 41 patients were recruited into cohort 1 (<i>n</i> = 17), cohort 2 (<i>n</i> = 4), and cohort 3 (<i>n</i> = 20). Seroconversion for SARS-CoV-2 neutralizing antibodies was reached by 50.0%, 100.0%, and 90.0% of patients at month 6 and by 81.3%, 100.0%, and 100.0% one month after booster (cohorts 1, 2, and 3, respectively). Antibody levels in cohort 1 increased after the booster compared to month 6 but remained lower compared to cohorts 2 and 3. T-cell responses were seen in 28.5%, 25.0%, and 73.7% at month 6 and in 28.6%, 50.0%, and 83.3% after the booster (cohorts 1, 2, and 3, respectively). In cohort 1, the extent of T-cell response was lower at month 6 compared to cohorts 2 and 3 but reached almost similar levels after the booster. Conclusions: The antibody and T-cell responses support SARS-CoV-2 (booster) vaccines in siponimod-treated patients. |
| first_indexed | 2024-03-10T23:30:50Z |
| format | Article |
| id | doaj.art-94ac80569d1548598bd16d4ac6113645 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2025-02-18T18:32:49Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-94ac80569d1548598bd16d4ac61136452024-10-21T16:29:49ZengMDPI AGVaccines2076-393X2023-08-01118137410.3390/vaccines11081374Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC)Tjalf Ziemssen0Marie Groth1Veronika Eva Winkelmann2Tobias Bopp3Department of Neurology, Center of Clinical Neuroscience, Carl Gustav Carus University Clinic, University Hospital of Dresden, Technische Universität Dresden, 01307 Dresden, GermanyNovartis Pharma GmbH, 90429 Nuremberg, GermanyNovartis Pharma GmbH, 90429 Nuremberg, GermanyInstitute for Immunology, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, GermanyBackground: Evidence on SARS-CoV-2 mRNA vaccination under siponimod treatment is rare. Methods: AMA-VACC is a prospective, open-label clinical study on SARS-CoV-2 mRNA vaccination during ongoing siponimod treatment (cohort 1), during siponimod interruption (cohort 2), or during treatment with other disease-modifying therapies or without therapy (cohort 3). SARS-CoV-2-specific antibodies and T-cell reactivity were measured six months after the initial vaccination and one month after the booster. Results: 41 patients were recruited into cohort 1 (<i>n</i> = 17), cohort 2 (<i>n</i> = 4), and cohort 3 (<i>n</i> = 20). Seroconversion for SARS-CoV-2 neutralizing antibodies was reached by 50.0%, 100.0%, and 90.0% of patients at month 6 and by 81.3%, 100.0%, and 100.0% one month after booster (cohorts 1, 2, and 3, respectively). Antibody levels in cohort 1 increased after the booster compared to month 6 but remained lower compared to cohorts 2 and 3. T-cell responses were seen in 28.5%, 25.0%, and 73.7% at month 6 and in 28.6%, 50.0%, and 83.3% after the booster (cohorts 1, 2, and 3, respectively). In cohort 1, the extent of T-cell response was lower at month 6 compared to cohorts 2 and 3 but reached almost similar levels after the booster. Conclusions: The antibody and T-cell responses support SARS-CoV-2 (booster) vaccines in siponimod-treated patients.https://www.mdpi.com/2076-393X/11/8/1374COVID-19 vaccinationsecondary progressive multiple sclerosisdisease-modifying therapyneutralizing antibodiesT-cell response |
| spellingShingle | Tjalf Ziemssen Marie Groth Veronika Eva Winkelmann Tobias Bopp Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC) Vaccines COVID-19 vaccination secondary progressive multiple sclerosis disease-modifying therapy neutralizing antibodies T-cell response |
| title | Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC) |
| title_full | Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC) |
| title_fullStr | Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC) |
| title_full_unstemmed | Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC) |
| title_short | Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC) |
| title_sort | immune response to initial and booster sars cov 2 mrna vaccination in patients treated with siponimod final analysis of a nonrandomized controlled clinical trial ama vacc |
| topic | COVID-19 vaccination secondary progressive multiple sclerosis disease-modifying therapy neutralizing antibodies T-cell response |
| url | https://www.mdpi.com/2076-393X/11/8/1374 |
| work_keys_str_mv | AT tjalfziemssen immuneresponsetoinitialandboostersarscov2mrnavaccinationinpatientstreatedwithsiponimodfinalanalysisofanonrandomizedcontrolledclinicaltrialamavacc AT mariegroth immuneresponsetoinitialandboostersarscov2mrnavaccinationinpatientstreatedwithsiponimodfinalanalysisofanonrandomizedcontrolledclinicaltrialamavacc AT veronikaevawinkelmann immuneresponsetoinitialandboostersarscov2mrnavaccinationinpatientstreatedwithsiponimodfinalanalysisofanonrandomizedcontrolledclinicaltrialamavacc AT tobiasbopp immuneresponsetoinitialandboostersarscov2mrnavaccinationinpatientstreatedwithsiponimodfinalanalysisofanonrandomizedcontrolledclinicaltrialamavacc |